Recruiting NCT06702111
Outcome of Allogeneic Hematopoietic Stem Cell Transplantation
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Hematopoietic Stem Cell Transplant (HSCT). Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Hong Kong
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in Adults: Clinical Outcome and Complications
Overview
To collect baseline and outcome data relating to all bone marrow, peripheral blood, cord blood hematopoietic stem cell transplants and therapies related to hematopoietic stem cell transplantation performed in Queen Mary Hospital.
Primary outcome measures
- Overall survival [Time frame: 5 year]
- Relapse-free survival [Time frame: 5 years]
Eligibility criteria
Inclusion criteria
- Adult patients aged 18 years or older who received allogeneic hematopoietic stem cell transplantation (allo-HSCT).
Exclusion criteria
- participant who is unable to give informed consent in a prospective cohort.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
Hong Kong · 2 centers
- Department of Medicine, Queen Mary Hospital — Hong Kong
- Queen Mary Hospital, Hong Kong — Hong Kong
Publications
- Passweg JR, Baldomero H, Chabannon C, Basak GW, de la Camara R, Corbacioglu S, Dolstra H, Duarte R, Glass B, Greco R, Lankester AC, Mohty M, Peffault de Latour R, Snowden JA, Yakoub-Agha I, Kroger N; European Society for Blood and Marrow Transplantation (EBMT). Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years. Bone Marrow PMID 33623153
- Leung GMK, Ye Y, Luo Y, Shi J, Zhao Y, Sim JPY, Kwong YL, He H, Gill H. A novel prognostic scoring system HATS for acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation. Ann Hematol. 2026 Apr 9;105(5):228. doi: 10.1007/s00277-026-06989-z. PMID 41954668
Identifiers
NCT: NCT06702111 · ALLO-HSCT-001